Clopidogrel

Product overview

Clopidogrel Pellets – Precision-Engineered for Reliable Antiplatelet Performance. Rraynex’s clopidogrel pellets are formulated using high-purity clopidogrel bisulfate, delivering stable, reproducible ADP receptor inhibition essential for dual antiplatelet therapy (DAPT) and cardiovascular care formulations. Manufactured through controlled granulation and layering systems, these pellets offer unmatched consistency, stability, and process reproducibility. Overview: Clopidogrel is a trusted antiplatelet prodrug that helps prevent blood clots in patients with heart disease, stroke risk, or peripheral arterial conditions. Our pelletised form enhances manufacturability and bioavailability consistency—supporting both monotherapy capsules and fixed-dose combination tablets used in cardiology and post-angioplasty regimens. Key Features & Benefits: • Uniform Pellet Morphology: Ensures consistent dissolution and reproducible drug release across capsule and tablet formats. • Stability Controlled Processing: Inline temperature and humidity mapping maintain clopidogrel integrity throughout granulation and coating. • High Flowability: Narrow particle size distribution reduces segregation and improves capsule fill uniformity. • Regulatory-Ready Documentation: Comparative dissolution profiles, nitrosamine risk assessments, and multi-pH dissolution data available. • Compatibility: Ideal for co-formulation with aspirin, atorvastatin, or other cardioprotective APIs. • Technical Support: Full assistance for gastro-resistant layering, lubricant optimization, and fill-weight adjustments during scale-up. Technical Specifications: • API: Clopidogrel Bisulfate • Assay: 98.0–102.0% • Pellet Size Range: 500–1000 μm (customizable) • Loss on Drying: ≤1.5% • Coating: Enteric or moisture-barrier optional • Packaging: 25 kg moisture-barrier HDPE drums with tamper-evident liners • Storage: Store below 25°C, protected from light and humidity. Applications: • Pharmaceutical manufacturers producing antiplatelet capsules or fixed-dose combinations. • Contract formulators requiring consistent pellet-based DAPT products. • Hospitals and B2B distributors sourcing bulk raw material for cardiovascular drug lines. Educational Insight: Clopidogrel acts by irreversibly blocking P2Y12 ADP receptors on platelets, reducing their ability to clump together and form clots. It is often prescribed after stent placement or heart attacks to reduce recurrent cardiovascular events. Pelletised clopidogrel ensures consistent absorption and reduced formulation variability, enhancing therapeutic reliability. SEO Keywords: clopidogrel pellets, antiplatelet pellets, clopidogrel bisulfate pellets, DAPT raw material, cardiovascular drug pellets, dual antiplatelet therapy supply, sustained-release clopidogrel, pharma pellets manufacturer, enteric coated clopidogrel, clopidogrel API pellets exporter Usage Note: For pharmaceutical manufacturing and educational purposes only. Patients should use clopidogrel-containing medicines strictly under medical supervision. Manufacturers should validate formulations in compliance with regional pharmacopeial and regulatory standards.